Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

IMCERA

Executive Summary

Will relocate corporate headquarters from Northbrook, Ill. to St. Louis next spring, Mallinckrodt parent announces Aug. 19. The move and continuing decentralization efforts at IMCERA will result in a reduction in size of the 120-person corporate staff to about 50 persons, the company says. Relocation and staff reduction costs will not affect FY 1994 earnings since these costs were factored into the previously announced FY 1993 corporate restructuring charge. Annual savings from the move to St. Louis and the downsizing are "expected to be several million dollars." Mallinckrodt Medical and Mallinckrodt Speciality Chemicals are both based in the St. Louis area, employing 27% of IMCERA's 10,000 worldwide employees and accounting for the majority of IMCERA sales and earnings. The changes will not affect IMCERA's Pitman- Moore animal health and nutrition company.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS023224

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel